Prof. Dr. YEŞİM ERALP

Yayın Ağı

Makaleler 129

1. Evolving Concepts and Contemporary Management of Early-Stage Breast Cancer: An Evidence-Based Approach to Grey Zones from a Comprehensive Breast Unit Part 2: Systemic Treatment

Şenocak Taşçı E., SÖNMEZ Ö., OYAN ULUÇ B., KORKMAZ T., YILDIZ İ., Bozkurt M., et al.

European Journal of Breast Health , cilt.22, sa.1, ss.1-18, 2026 (ESCI, Scopus, TRDizin)

2. Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer

Cortés J., Punie K., Eralp Y.

NEW ENGLAND JOURNAL OF MEDICINE , sa.19, ss.1912-1925, 2025 (SCI-Expanded, Scopus)

3. First-line (1L) ribociclib (RIB) plus endocrine therapy (ET) vs combination chemotherapy (combo CT) in clinically aggressive HR+/HER2-advanced breast cancer (ABC): a subgroup analysis of RIGHT Choice by intrinsic subtype & gene & signature expression

Lu Y., Hsu C., Mahidin E. I. B. M., Gupta S., Goekmen E., Artamonova E., et al.

CLINICAL CANCER RESEARCH , cilt.31, sa.12, 2025 (SCI-Expanded, Scopus)

4. First-line (1L) ribociclib (RIB) plus endocrine therapy (ET) vs combination chemotherapy (combo CT) in clinically aggressive hormone receptor (HR)+/HER2-advanced breast cancer (ABC): A subgroup analysis of patients (pts) with or without liver metastases (mets) from RIGHT Choice.

El Saghir N. S., Im S., Azim H. A., Eralp Y., Yap Y. S., Sandhu M. S., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.43, sa.16_SUPPL, 2025 (SCI-Expanded, Scopus)

5. Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women with Clinically Aggressive Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer

Mahidin E. I. B. M., Im S., Rihani J., Chung W., Babu K. G., Bowles J., et al.

Journal of Clinical Oncology , cilt.42, sa.23, ss.2812-2821, 2024 (SCI-Expanded, Scopus)

6. A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy

Kilickap S., Ozturk A., Karadurmus N., Korkmaz T., Yumuk P. F., Cicin I., et al.

MEDICINE , cilt.103, sa.21, 2024 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

7. Is there any prognostic significance in pleural involvement and/or effusion in patients with ALK-positive NSCLC?

Guner G., Aktas B. Y., Basal F. B., DEMİRKAZIK A., Gursoy P., Demirci U., et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , cilt.149, sa.14, ss.13271-13277, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

8. Clinical Applications of Combined Immunotherapy Approaches in Gastrointestinal Cancer: A Case-Based Review

ERALP Y., Ates U.

Vaccines , cilt.11, sa.10, 2023 (SCI-Expanded, Scopus)

9. Outcomes with first-line (1L) ribociclib (RIB) plus endocrine therapy (ET) vs physician's choice combination chemotherapy (combo CT) by age in pre/perimenopausal patients (pts) with aggressive HR+/HER2-advanced breast cancer (ABC): A subgroup analysis of the RIGHT Choice trial

El Saghir N. S., Yap Y. S., Eralp Y., Im S., Azim H. A., Rihani J., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.41, sa.16_SUPPL, ss.1063, 2023 (SCI-Expanded, Scopus)

10. Demographic and Clinical Features of Patients with Metastatic Breast Cancer: A Retrospective Multicenter Registry Study of the Turkish Oncology Group

DOĞAN İ., AKSOY S., ÇAKAR B., BAŞARAN G., Ercelep O., Mandel N. M., et al.

CANCERS , sa.6, 2023 (SCI-Expanded, Scopus)

11. Lung Cancer in Turkey

KAYI CANGIR A., Yumuk P. F., SAK S., AKYÜREK S., ERALP Y., Yilmaz U., et al.

JOURNAL OF THORACIC ONCOLOGY , cilt.17, sa.10, ss.1158-1170, 2022 (SCI-Expanded, Scopus)

12. Application of mRNA Technology in Cancer Therapeutics

ERALP Y.

VACCINES , cilt.10, sa.8, 2022 (SCI-Expanded, Scopus)

13. Laterality and survival in mesothelioma: A SEER database analysis.

Parekh J., Yerlikaya A., Xie Y., Eralp Y., Adjepong Y.

JOURNAL OF CLINICAL ONCOLOGY , sa.16, 2022 (SCI-Expanded, Scopus)

14. International Association for the Study of Lung Cancer Study of the Impact of Coronavirus Disease 2019 on International Lung Cancer Clinical Trials

Smeltzer M. P., Scagliotti G., Wakelee H. A., Mitsudomi T., Roy U. B., Clark R. C., et al.

JOURNAL OF THORACIC ONCOLOGY , cilt.17, sa.5, ss.651-660, 2022 (SCI-Expanded, Scopus)

15. Factors predicting a lower likelihood of residual nodal disease in clinically-node positive patients undergoing sentinel node surgery after neoadjuvant chemotherapy for breast cancer

Cabioglu N., KARANLIK H., Igci A., Muslumanoglu M., TÜKENMEZ M., EMİROĞLU S., et al.

CANCER RESEARCH , sa.4, 2022 (SCI-Expanded, Scopus)

16. The Impact of Hybrid Capture-Based Comprehensive Genomic Profiling on Treatment Strategies in Patients with Solid Tumors

Dişel U., Köse F., Bilici A., Özgüroğlu M., Sağlam S., Şeker M., et al.

Journal of Oncological Science , cilt.8, sa.2, ss.87-93, 2022 (Scopus, TRDizin)

17. Correlation between clinicopathologic factors and recurrence score according to TAILOR x risk category in patients with hormone receptor positive early-stage breast cancer

Pilanci K. N., Unal C., Ordu C., Gokmen E., Ozdogan M., Guler N., et al.

Journal of B.U.ON. , cilt.26, sa.6, ss.2266-2273, 2021 (SCI-Expanded, Scopus)

18. Outcomes of thymoma after multimodal therapy and determinants of survival: A 16-year experience of a tertiary cancer center

AK N., Toker A., KARA M., ÖZKAN B., Ulker M., Kaba E., et al.

TURK GOGUS KALP DAMAR CERRAHISI DERGISI-TURKISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY , cilt.29, sa.4, ss.487-495, 2021 (SCI-Expanded, Scopus)

19. The role of adjuvant chemotherapy in resected stage I non - small cell lung cancer: A Turkish Oncology Group Study.

Ak N., Ozkan B., Yenigun M. B., Yilmazbayhan D., Toker A., Ferhatoglu F., et al.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology , cilt.26, sa.3, ss.819-829, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

20. TIM3 expression on TILs is associated with poor response to neoadjuvant chemotherapy in patients with locally advanced triple-negative breast cancer

CABIOĞLU N., ÖNDER S., Oner G., Karatay H., TÜKENMEZ M., Muslumanoglu M., et al.

BMC CANCER , cilt.21, sa.1, 2021 (SCI-Expanded, Scopus)

21. GLASS: Global Lorlatinib for ALK(+) and ROS1(+) Retrospective Study: Real World Data of 123 NSCLC Patients

Peled N., Gillis R., Kilickap S., Froesch P., Orlov S., Filippova E., et al.

JOURNAL OF THORACIC ONCOLOGY , cilt.16, sa.3, 2021 (SCI-Expanded, Scopus)

22. Tim3 expression on tumor infiltrating lymphocytes is associated with poor response to neoadjuvan chemotherapy in patients with locally advanced triple negative breast cancer

CABIOĞLU N., ÖNDER S., Oner G., Karatay H., TÜKENMEZ M., Muslumanoglu M., et al.

CANCER RESEARCH , sa.4, 2021 (SCI-Expanded, Scopus)

23. GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients

Peled N., Gillis R., KILIÇKAP S., Froesch P., Orlov S., Filippova E., et al.

LUNG CANCER , cilt.148, ss.48-54, 2020 (SCI-Expanded, Scopus)

24. Turkish national consensus on breast cancer management during temporary state of emergency due to COVID-19 outbreak

Sezer A., ÇİÇİN İ., Cakmak G. K., Gurdal S. O., Basaran G., Oyan B., et al.

TURKISH JOURNAL OF SURGERY , cilt.36, sa.2, ss.147-163, 2020 (ESCI, Scopus, TRDizin)

25. Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial

Demir A., Mandel N. M., PAYDAŞ S., Demir G., ER O., Turhal N. S., et al.

Balkan medical journal , cilt.37, sa.2, ss.104-107, 2020 (SCI-Expanded, Scopus, TRDizin) Sürdürülebilir Kalkınma

26. Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial.

Demir A., Molinas Mandel N., Paydaş S., Demir O. G., Er Ö., Turhal N. S., et al.

Balkan Medical Journal , cilt.37, sa.2, ss.104-107, 2020 (SCI-Expanded, Scopus, TRDizin) Sürdürülebilir Kalkınma

27. Clinical feasibility of NGS liquid biopsy analysis in NSCLC patients

Papadopoulou E., Tsoulos N., Tsantikidi K., Metaxa-Mariatou V., Stamou P. E., Kladi-Skandali A., et al.

PLOS ONE , cilt.14, sa.12, 2019 (SCI-Expanded, Scopus)

28. The Role Adjuvant Chemotherapy in Resected Stage 1 NSCLC with High Risk Factors: A Turkish Oncology Group Study

Eralp Y., AK N., Yilmazbayhan D., ÖZKAN B., FERHATOĞLU F., DEMİRKAZIK A., et al.

JOURNAL OF THORACIC ONCOLOGY , sa.10, 2019 (SCI-Expanded, Scopus)

29. Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey

Kilickap S., Demirci U., Bugdayci F., Tural D., KORKMAZ T., PAYDAŞ S., et al.

JOURNAL OF THORACIC ONCOLOGY , sa.10, 2019 (SCI-Expanded, Scopus)

30. Outcomes of Thymoma and Determinants of Survival: 16 Years Experience of a Tertiary Cancer Center

AK N., Toker A., Bayraktar S., ÖZKAN B., ÜLKER M. G., Dagoglu N., et al.

JOURNAL OF THORACIC ONCOLOGY , sa.10, 2019 (SCI-Expanded, Scopus)

31. Crizotinib Efficacy in ALK-Positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experience from Turkey

Kilickap S., Ozturk A., Karadurmus N., Korkmaz T., Yumuk P., ÇİÇİN İ., et al.

JOURNAL OF THORACIC ONCOLOGY , sa.10, 2018 (SCI-Expanded, Scopus)

32. Prognostic Significance of Adjuvant Chemotherapy Induced Amenorrhea in Luminal A and B Subtypes

Ordu C., Pilanci K. N., Alco G., Elbuken F., Koksal U. I., Ilgun S., et al.

EUROPEAN JOURNAL OF BREAST HEALTH , cilt.14, sa.3, ss.173-179, 2018 (Hakemli Dergi)

33. Possible role of stress, coping strategies, and life style in the development of breast cancer

YILDIRIM N., ÖZKAN M., Ilgun A. S., Sarsenov D., Alco G., Aktepe F., et al.

INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE , cilt.53, sa.3, ss.207-220, 2018 (SCI-Expanded, SSCI, Scopus) Sürdürülebilir Kalkınma

34. Impact of Personality Traits, Anxiety, Depression and Hopelessness Levels on Quality of Life in the Patients with Breast Cancer

Izci F., Sarsanov D., Erdogan Z. I., Ilgun A. S., Celebi E., Alco G., et al.

EUROPEAN JOURNAL OF BREAST HEALTH , cilt.14, sa.2, ss.105-111, 2018 (Hakemli Dergi)

35. Preoperative Lymphedema-Related Risk Factors in Early-Stage Breast Cancer

Iyigun Z. E., Duymaz T., Ilgun A. S., Alco G., Ordu C., Sarsenov D., et al.

LYMPHATIC RESEARCH AND BIOLOGY , cilt.16, sa.1, ss.28-35, 2018 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

36. Roles of Biopsychosocial Factors in the Development of Breast Cancer

ÖZKAN M., Yildirim N., Disci R., Ilgun A. S., Sarsenov D., Alco G., et al.

EUROPEAN JOURNAL OF BREAST HEALTH , cilt.13, sa.4, ss.206-212, 2017 (Hakemli Dergi)

37. Receptor discordance rate and its effects on survival in primary and recurrent breast cancer patients

Ilgun S., Sarsenov D., Erdogan Z., Ordu C., Celebi F., Pilanci K. N., et al.

JOURNAL OF BUON , cilt.21, sa.6, ss.1425-1432, 2016 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

38. The Role of Genomic Profiling in Advanced Breast Cancer: The Two Faces of Janus.

Eralp Y.

Translational oncogenomics , cilt.8, ss.1-7, 2016 (Hakemli Dergi)

39. The Relationship between Bone Mineral Density and Estrogen Receptor Positivity in Patients with Breast Cancer

Iyigun Z. E., Pilanci K. N., Cabuk F. K., Ilgun S., Ordu C., Duymaz T., et al.

JOURNAL OF BREAST HEALTH , sa.3, ss.119-122, 2016 (ESCI, TRDizin)

40. Concomitant etoposide and cisplatin provided improved survival compared with docetaxel and cisplatin in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy

Sen F., Tambas M., Ozkaya K., Guveli M. E., Ciftci R., Ozkan B., et al.

MEDICINE , cilt.95, sa.30, 2016 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

41. The Prognostic Impact of Molecular Subtypes and Very Young Age on Breast Conserving Surgery in Early Stage Breast Cancer

Ordu C., McGuire K., Alco G., Pilanci K. N., Koksal U. I., Elbuken F., et al.

CUREUS , cilt.8, sa.6, 2016 (Hakemli Dergi)

42. True Local Recurrences after Breast Conserving Surgery have Poor Prognosis in Patients with Early Breast Cancer

Sarsenov D., Ilgun S., Ordu C., Alco G., Bozdogan A., Elbuken F., et al.

CUREUS , cilt.8, sa.3, 2016 (Hakemli Dergi) Sürdürülebilir Kalkınma

43. Metaplastic Breast Carcinoma Versus Triple-Negative Breast Cancer Survival and Response to Treatment

AYDINER A., Sen F., Tambas M., Ciftci R., Eralp Y., Saip P., et al.

MEDICINE , cilt.94, sa.52, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

44. The effect of internal mammary lymph node biopsy on the therapeutic decision and survival of patients with breast cancer

ÖZMEN V., ÖZÇINAR B., Bozdogan A., Eralp Y., YAVUZ E., DİNÇER M. Z.

EJSO , cilt.41, sa.10, ss.1368-1372, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

45. Clinicopathological Data's of Advanced NSCLC Patients with ROS1 Gene Rearrangement and of Clinical Responses to Crizotinib in TURKEY

Oz B., BATUR Ş., ERALP Y., Hasturk S., Yumuk F., Yildiz O., et al.

JOURNAL OF THORACIC ONCOLOGY , cilt.10, sa.9, 2015 (SCI-Expanded, Scopus)

46. Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG)

Icli F., Altundag K., AKBULUT H., PAYDAŞ S., BAŞARAN G., SAİP P. M., et al.

BREAST CANCER , cilt.22, sa.5, ss.480-485, 2015 (SCI-Expanded, Scopus)

47. Concomitant Chemoradiotherapy with Etoposide & Cisplatin versus Docetaxel & Cisplatin in Locally Advanced Non-Small Cell Lung Cancer

ERALP Y., Sen F., Tambas M., ÖZKAYA TORAMAN K., ÖZKAN B., ORAL E. N., et al.

JOURNAL OF THORACIC ONCOLOGY , cilt.10, sa.9, 2015 (SCI-Expanded, Scopus)

48. Is Administration of Trastuzumab an Independent Risk Factor for Developing Osteonecrosis of the Jaw Among Metastatic Breast Cancer Patients Under Zoledronic Acid Treatment?

Pilanci K. N., Alco G., Ordu C., Sarsenov D., Celebi F., Erdogan Z., et al.

MEDICINE , cilt.94, sa.18, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

49. Prognostic value of receptor status change following neoadjuvant chemotherapy in locally advanced breast cancer

Ozmen V., Atasoy A., Bozdogan A., Dincer M., Eralp Y., Tuzlali S.

Cancer Treatment Communications , cilt.4, ss.89-95, 2015 (Scopus)

50. The Outcome of Patients with Triple Negative Breast Cancer: The Turkish Oncology Group Experience

Eralp Y., Kilic L., Alco G., BAŞARAN G., Dogan M., Dincol D., et al.

JOURNAL OF BREAST HEALTH , cilt.10, sa.4, ss.209-215, 2014 (ESCI)

51. Abundant circulating microRNAs in breast cancer patients fluctuate considerably during neoadjuvant chemotherapy

GEZER U., Keskin S., Igci A., TÜKENMEZ M., Tiryakioglu D., Cetinkaya M., et al.

ONCOLOGY LETTERS , cilt.8, sa.2, ss.845-848, 2014 (SCI-Expanded, Scopus)

52. Is there any diagnostic value of serum protease-activated receptor-1 (PAR1) levels on determination of epithelial ovarian carcinoma?

Karabulut S., Aksit E., Tas F., Ciftci R., Aydiner A., Yildiz İ., et al.

TUMOR BIOLOGY , cilt.35, sa.5, ss.4323-4329, 2014 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

53. The predictive and prognostic role of tumoral miRNA expression levels in patients with breast cancer (BC) treated with neoadjuvant chemotherapy (NAC)

ERALP Y., Keskin S., GEZER U., TÜKENMEZ M., Muslumanoglu M., Dalay N., et al.

CANCER RESEARCH , cilt.73, 2013 (SCI-Expanded, Scopus)

54. Which cytologically proven node-positive breast cancer patients can avoid axillary lymph dissection after neaodjuvant chemotherapy?

KARANLIK H., Ilhan B., Fayda M., Yavuz E., Mudun A., SAİP P. M., et al.

CANCER RESEARCH , cilt.73, 2013 (SCI-Expanded, Scopus)

55. Phase II study of lapatinib in combination with vinorelbine in patients with HER2 positive recurrent or metastatic breast cancer: A multicentric Turkish Oncology Group (TOG) trial

SAİP P. M., Eralp Y., AYDOĞMUŞ ŞEN F., Karaca H., ÖZKAN M., ÇETİN B. E., et al.

BREAST , cilt.22, sa.5, ss.628-633, 2013 (SCI-Expanded, Scopus)

56. A high serum level of M65 is associated with tumour aggressiveness and an unfavourable prognosis for epithelial ovarian cancer

Yildiz İ., Tas F., Kilic L., Sen F., Saip P., Eralp Y., et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY , cilt.72, sa.2, ss.437-444, 2013 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

57. Predictive Role of Midtreatment Changes in Survivin, GSTP1, and Topoisomerase 2 alpha Expressions for Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer

Eralp Y., Keskin S., YÖRÜKER E. E., Akisik E., Igci A., Muslumanoglu M., et al.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS , cilt.36, sa.3, ss.215-223, 2013 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

58. Association of clinical and pathological variables with survival in thymoma

AYDINER A., Toker A., Sen F., Bicakci E., KAYTAN SAĞLAM E., Erus S., et al.

MEDICAL ONCOLOGY , cilt.29, sa.3, ss.2221-2228, 2012 (SCI-Expanded, Scopus)

59. Phase II study of loading-dose ibandronate treatment in patients with breast cancer and bone metastases suffering from moderate to severe pain

Altundag K., DİZDAR Ö., Ozsaran Z., Ozkok S., Saip P., Eralp Y., et al.

Onkologie , cilt.35, sa.5, ss.254-258, 2012 (SCI-Expanded, Scopus)

60. Induction Chemotherapy With Triweekly Docetaxel and Cisplatin Followed by Concomitant Chemoradiotherapy With or Without Surgery in Stage III Non-Small-Cell Lung Cancer: A Phase II Study

Aydiner A., Sen F., KAYTAN SAĞLAM E., Oral E. N., Eralp Y., TAŞ F., et al.

CLINICAL LUNG CANCER , cilt.12, sa.5, ss.286-292, 2011 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

61. Trastuzumab use and survival in HER2 (+) nonmetastatic breast cancer among Turkish women

Kayahan M., Kadioglu H., Muslumanoglu M., Igci A., Ozmen V., Idiz O., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.29, sa.27, 2011 (SCI-Expanded, Scopus)

62. Phase II study of lapatinib in combination with vinorelbine in patients with ErbB2-amplified recurrent or metastatic breast cancer

SAİP P. M., Eralp Y., Ozkan M., Karaca H., Benekli M., Cetin B., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.29, sa.15, 2011 (SCI-Expanded, Scopus)

63. Nine versus 52 weeks of adjuvant trastuzumab in early breast cancer: An observational study of the Turkish Oncology Group.

Icli F., Altundag K., Coskun U., Paydas S., BAŞARAN G., SAİP P. M., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.29, sa.15, 2011 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

64. Glutathione S-transferase P1 polymorphisms are associated with time to tumor progression in small cell lung cancer patients

Saip P., Sen F., Vural B., Ugurel E., Demirkan A., Derin D., et al.

JOURNAL OF BUON , cilt.16, sa.2, ss.241-246, 2011 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

65. Clinical and Pathological Features of Breast Cancer Associated with the Pathological Complete Response to Anthracycline-Based Neoadjuvant Chemotherapy

Keskin S., Muslumanoglu M., Saip P., Karanlik H., Guveli M., Pehlivan E., et al.

ONCOLOGY , cilt.81, sa.1, ss.30-38, 2011 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

66. Phase II study of loading-dose ibandronate treatment in patients in breast cancer and bone metastases suffering from moderate to severe pain

Dizdar O., Altundag M. K., Ozkok S., Ozsaran Z., SAİP P. M., ERALP Y., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.28, sa.15, 2010 (SCI-Expanded, Scopus)

67. Association between glutathione s-transferase P1 polymorphisms and time to tumor progression in small cell lung cancer patients.

Saip P., Sen F., Vural B., Ugurel E., Demirkan A., Derin D., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.28, sa.15, 2010 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

68. Yolk sac tumours of the ovary: Evaluation of clinicopathological features and prognostic factors

Cicin I., Saip P., Guney N., Eralp Y., Ayan I., KEBUDİ R., et al.

EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY , cilt.146, sa.2, ss.210-214, 2009 (SCI-Expanded, Scopus)

69. Identification of patients who may benefit from the prophylactic cranial radiotherapy among breast cancer patients with brain metastasis

Saip P., Cicin I., Eralp Y., Karagol H., Kucucuk S., Alas R. C., et al.

JOURNAL OF NEURO-ONCOLOGY , cilt.93, sa.2, ss.243-251, 2009 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

70. BORDERLINE RESECTIONS AFTER NEO-ADJUVANT TREATMENT: SLEEVE LOBECTOMY VS. PNEUMONECTOMY

Toker A., ÖZKAN B., Tanju S., Ziyade S., ERELEL M., Saglam E. K., et al.

LUNG CANCER , cilt.64, 2009 (SCI-Expanded, Scopus)

71. Malignant Ovarian Germ Cell Tumors A Single-Institution Experience

Cicin I., Eralp Y., Saip P., Ayan I., Kebudi R., Iyibozkurt C., et al.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS , cilt.32, sa.2, ss.191-196, 2009 (SCI-Expanded, Scopus)

72. Factors related to recurrence after pathological complete response to postoperative chemotherapy in patients with epithelial ovarian cancer.

Karagol H., Saip P., Eralp Y., Topuz S., Berkman S., Ilhan R., et al.

Tumori , cilt.95, ss.207-11, 2009 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

73. Clinical features associated with a favorable outcome following neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger

Eralp Y., Smith T. L., Altundag K., Kau S., Litton J., Valero V., et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , cilt.135, sa.1, ss.141-148, 2009 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

74. Primary Tubal Cancers: A Clinicopathological Study of Twenty Cases

Yesil Onder S., Yavuz E., Tuzlali S., Ilhan R., TOPUZ S., Iyibozkurt A. C., et al.

TURKISH JOURNAL OF PATHOLOGY , cilt.25, sa.3, ss.85-89, 2009 (ESCI, TRDizin) Sürdürülebilir Kalkınma

75. TRASTUZUMAB BEYOND PROGRESSION IN PATIENTS WITH HER-2/NEU POSITIVE METASTATIC BREAST CANCER

ERALP Y.

JOURNAL OF BREAST HEALTH , cilt.5, sa.1, ss.3-8, 2009 (ESCI) Sürdürülebilir Kalkınma

76. Factors affecting the prognosis of breast cancer patients with brain metastases

Saip P., Cicin I., Eralp Y., Kucucuk S., Tuzlali S., Karagol H., et al.

BREAST , cilt.17, sa.5, ss.451-458, 2008 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

77. .ROLE OF VARIOUS METHODS OF BRACHYTHERAPY IN CARCINOMA OF VAGINA

Kucucuk S., SARPER E. B., Aslay I., Kemikler G., Ozbay I., Dincer M., et al.

RADIOTHERAPY AND ONCOLOGY , cilt.88, 2008 (SCI-Expanded, Scopus)

78. Ovarian carcinoma with simultaneous breast and rectum metastases

Derin D., Eralp Y., Guney N., ÖZLÜK M. Y., Topuz E.

Onkologie , cilt.31, sa.4, ss.200-202, 2008 (SCI-Expanded, Scopus)

79. Impact of adjuvant chemotherapy with respect to level of hormone receptor expression in patients with hormone responsive breast cancer: Implications for endocrine resistance

Eralp Y., Sakallioglu B., Kucucuk S., Tuzlali S., Saip P., Igci A., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.26, sa.15, 2008 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

80. MAPK overexpression is associated with anthracycline resistance and increased risk for recurrence in patients with triple-negative breast cancer

Eralp Y., Derin D., ÖZLÜK M. Y., Yavuz E., Guney N., SAİP P. M., et al.

Annals of Oncology , cilt.19, sa.4, ss.669-674, 2008 (SCI-Expanded, Scopus)

81. Predictive factors for local recurrence after breast conservative surgery following neoadjuvant chemotherapy: our long-term results

Cabioglu N., Muslumanoglu M., Igci A., ÖZÇINAR B., Ozmen V., Dagoglu T., et al.

TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY , cilt.23, sa.2, ss.81-90, 2008 (ESCI, Scopus, TRDizin) Sürdürülebilir Kalkınma

82. Size distribution of circulating cell-free DNA in sera of breast cancer patients in the course of adjuvant chemotherapy

GEZER U., Eralp Y., YÖRÜKER E. E., Akisik E. Z., Saip P., Topuz E., et al.

CLINICAL CHEMISTRY AND LABORATORY MEDICINE , cilt.46, sa.3, ss.311-317, 2008 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

83. Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer

Derin D., Eralp Y., Ozluk Y., Yavuz E., Guney N., Saip P., et al.

CANCER INVESTIGATION , cilt.26, sa.7, ss.671-679, 2008 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

84. Ovarian carcinosarcomas: Clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum

Cicin I., SAİP P. M., ERALP Y., Selam M., TOPUZ S., ÖZLÜK M. Y., et al.

GYNECOLOGIC ONCOLOGY , cilt.108, sa.1, ss.136-140, 2008 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

85. Effect of adjuvant chemotherapy on integrity of free serum DNA in patients with breast cancer

GEZER U., Eralp Y., Akisik E. Z., YÖRÜKER E. E., Saip P., Topuz E., et al.

CIRCULATING NUCLEIC ACIDS IN PLASMA AND SERUM V , cilt.1137, ss.175-179, 2008 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

86. Leptomeningeal dissemination of ovarian carcinoma through a ventriculopenitoneal shunt

Eralp Y., Saip P., Aydin Z., Berkman S., Topuz E.

GYNECOLOGIC ONCOLOGY , cilt.108, sa.1, ss.248-250, 2008 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

87. Multifocal breast cancer in women <= 35 years old

Litton J. K., Eralp Y., Gonzalez-Angulo A. M., Broglio K., Uyei A., Hortobagyi G. N., et al.

CANCER , cilt.110, sa.7, ss.1445-1450, 2007 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

88. The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer

KARAGÖL H., Saip P., Uygun K., Caloglu M., Eralp Y., TAŞ F., et al.

Medical Oncology , cilt.24, sa.1, ss.39-43, 2007 (SCI-Expanded, Scopus)

89. Women age <= 35 years with primary breast carcinoma - Disease features at presentation

Gonzalez-Angulo A., Broglio K., Kau S., Eralp Y., Erlichman J., Valero V., et al.

CANCER , cilt.103, sa.12, ss.2466-2472, 2005 (SCI-Expanded, Scopus)

90. The prevalence and determinants of the use of complementary and alternative medicine in adult Turkish cancer patients

TAŞ F., Ustuner Z., CAN G., ERALP Y., Camlica H., BAŞARAN M., et al.

ACTA ONCOLOGICA , cilt.44, sa.2, ss.161-167, 2005 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

91. Induction and concurrent chemotherapy with concomitant boost radiotherapy in non-small cell lung cancer

Oral E., Aydiner A., Eralp Y., Topuz E.

MEDICAL ONCOLOGY , cilt.22, sa.4, ss.367-374, 2005 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

92. Thymidine labeling index: Prognostic role in breast cancer

Bilir A., Eralp Y., CABIOĞLU N., Agizhali B., Camlica H., Aydiner A.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS , cilt.27, sa.4, ss.400-406, 2004 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

93. Efficacy of intraperitoneal cisplatin as consolidation therapy in patients with pathologic complete remission following front-line therapy for epithelial ovarian cancer - Consolidative intraperitoneal cisplatin in ovarian cancer

Topuz E., Eralp Y., Saglam S., Saip P., Aydiner A., Berkman S., et al.

GYNECOLOGIC ONCOLOGY , cilt.92, sa.1, ss.147-151, 2004 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

94. Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model

Eralp Y., Wang X., Wang J., Maughan M., Polo J., Lachman L.

BREAST CANCER RESEARCH , cilt.6, sa.4, 2004 (SCI-Expanded, Scopus)

95. Women aged 35 years or younger with primary breast carcinoma: Disease features at presentation

Gonzalez-Angulo A. M., Broglio K., Eralp Y., Kau S., Erlichman J., Valero V., et al.

ANNALS OF ONCOLOGY , cilt.15, ss.58, 2004 (SCI-Expanded, Scopus)

96. Prognostic factors in localized soft-tissue sarcomas.

Kaytan E., Yaman F., Cosar R., Eralp Y., Saip P., Darendeliler E.

American journal of clinical oncology , cilt.26, ss.411-5, 2003 (SCI-Expanded, Scopus)

97. Oral etoposide (VP16) in platinum-resistant epithelial ovarian cancer (EOC).

Alici S., Saip P., Eralp Y., Aydiner A., Topuz E.

American journal of clinical oncology , cilt.26, sa.4, ss.358-62, 2003 (SCI-Expanded, Scopus)

98. Prognostic factors and survival in patients with metastatic or recurrent carcinoma of the uterine cervix

Eralp Y., Saip P., Sakar B., Kucucuk S., Aydiner A., Dincer M., et al.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER , cilt.13, sa.4, ss.497-504, 2003 (SCI-Expanded, Scopus)

99. Prognostic factors in localized aggressive non-Hodgkin's lymphoma

Alici S., Bavbek S. E., Kaytan E., Eralp Y., Onat H.

American Journal of Clinical Oncology: Cancer Clinical Trials , cilt.26, sa.1, ss.1-5, 2003 (SCI-Expanded, Scopus)

100. Efficacy of cisplatin and cyclophosphamide combination for recurrent and metastatic carcinoma of the uterine cervix.

Eralp Y., Saip P., Sakar B., Tas F., Aydiner A., Topuz E.

European journal of gynaecological oncology , cilt.24, sa.3-4, ss.323-6, 2003 (SCI-Expanded, Scopus)

101. Resectable thymoma: Treatment outcome and prognostic factors in the late adolescent and adult age group

Eralp Y., Aydiner A., Kizir A., Kaytan E., Oral E., Topuz E.

CANCER INVESTIGATION , cilt.21, sa.5, ss.737-743, 2003 (SCI-Expanded, Scopus)

102. An atypical presentation of metastatic gestational choriocarcinoma with maxillary sinus and subcutaneous involvement; report of a case with literature review.

Alici S., Bavbek S. E., Eralp Y., Argon A., Basaran M., Aydiner A., et al.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology , cilt.7, sa.4, ss.373-6, 2002 (Scopus)

103. Aggressive non-Hodgkin's lymphoma treated at the Institute of Oncology, Istanbul: Treatment, outcome, and prognostic factors

Alici S., Bavbek S. E., Kaytan E., Başaran M., Eralp Y., Onat H.

American Journal of Clinical Oncology: Cancer Clinical Trials , cilt.25, sa.5, ss.502-508, 2002 (SCI-Expanded, Scopus)

104. An atypical presentation of metastatic gestational choriocarcinoma with maxillary sinus and subscutaneous involvement; Report of a case with literature review

Alici S., Bavbek S., Eralp Y., Argon A., BAŞARAN M., AYDINER A., et al.

Journal of B.U.ON. , cilt.7, sa.4, ss.373-376, 2002 (Scopus)

105. Anemia in oncology practice: Relation to diseases and their therapies

TAŞ F., Eralp Y., BAŞARAN M., ŞAKAR B., Alici S., Argon A., et al.

American Journal of Clinical Oncology: Cancer Clinical Trials , cilt.25, sa.4, ss.371-379, 2002 (SCI-Expanded, Scopus)

106. Prognostic factors and survival in late adolescent and adult patients with small round cell tumors

Eralp Y., Bavbek S., Başaran M., Kaytan E., Yaman F., Bilgiç B., et al.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS , cilt.25, sa.4, ss.418-424, 2002 (SCI-Expanded, Scopus)

107. Clinical characteristics of gestational trophoblastic disease at a single institute

Alici S., Eralp Y., Saip P., Argon A., BAŞARAN M., Topuz E., et al.

Tohoku Journal of Experimental Medicine , cilt.197, sa.2, ss.95-100, 2002 (SCI-Expanded, Scopus)

108. Treatment of aggressive non-Hodgkin's lymphoma with dose-intensified epirubicin in combination of cyclophosphamide, vincristine, and prednisone (CEOP-100) - A phase II study

Basaran M., Bavbek E., Sakar B., Eralp Y., Alici S., TAŞ F., et al.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS , cilt.24, sa.6, ss.570-575, 2001 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

109. Circulating HER-2/NEU levels in patients with melanoma.

ERALP Y., Aydiner A., Toptani S., TAŞ F., Camlica H., Topuz E.

CLINICAL CANCER RESEARCH , cilt.7, sa.11, 2001 (SCI-Expanded, Scopus)

110. Thymidine labeling index in epithelial ovarian cancer

Salihoglu Y., Bilir A., Aydiner A., Erkan M., Tuzlali S., Eralp Y.

INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS , cilt.75, sa.2, ss.171-176, 2001 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

111. Stevens-Johnson syndrome in a patient receiving anticonvulsant therapy during cranial irradiation

ERALP Y., Aydiner A., TAŞ F., SAİP P. M., Topuz E.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS , cilt.24, sa.4, ss.347-350, 2001 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

112. 5-fluorouracil-induced balanitis in a patient with oesophageal carcinoma

TAŞ F., BAŞARAN M., Aydiner A., ERALP Y., Topuz E.

CLINICAL ONCOLOGY , cilt.13, sa.3, ss.170-171, 2001 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

113. The role of chemotherapy in malignant mixed mullerian tumors of the female genital tract

Topuz E., ERALP Y., Aydiner A., SAİP P. M., TAŞ F., Yavuz E., et al.

EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY , cilt.22, sa.6, ss.469-472, 2001 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

114. The impact of penicillamine and zinc in hepatic and brain tissues of copper-overloaded rats

Özçelik D., ERALP Y., Öztekin G., Dursun S., Uzunismail H.

TRACE ELEMENTS AND ELECTROLYTES , cilt.18, sa.1, ss.34-38, 2001 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

115. The efficacy of combination chemotherapy including intraperitoneal cisplatinum and mitoxantrone with intravenous ifosfamide in patients with FIGO stage IC ovarian carcinoma

Topuz E., ERALP Y., SAİP P. M., Aydiner A., TAŞ F., Salihoglu Y., et al.

EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY , cilt.22, sa.1, ss.70-73, 2001 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

116. Prognostic factors and survival in patients with metastatic soft tissue sarcoma

Eralp Y., Bavbek S., Basaran M., Kaytan E., Yaman F., Eralp L., et al.

Journal of B.U.ON. , cilt.5, sa.3, ss.281-286, 2000 (Scopus)

117. A comparison of lansoprazole and omeprazole based triple combinations for the treatment of Helicobacter pylori associated gastritis and peptic ulcer

Eralp Y., DOBRUCALI A. M., Bagatur N., ÇELİK A. F., Davutoglu C., Tuncer M., et al.

Turkish Journal of Gastroenterology , cilt.11, sa.1, ss.25-29, 2000 (Scopus, TRDizin)

118. Prognostic factors and survival in adult patients with small round cell tumors.

ERALP Y., Bavbek S., BAŞARAN M., Kaytan E., Yaman F., Bilgiç B., et al.

ANNALS OF ONCOLOGY , cilt.11, ss.126, 2000 (SCI-Expanded, Scopus)

119. The role of chemotherapy in malignant mixed mullerian tumors of the female genital tract.

Topuz E., ERALP Y., AYDINER A., SAİP P. M., TAŞ F., Yavuz E., et al.

ANNALS OF ONCOLOGY , cilt.11, ss.87-88, 2000 (SCI-Expanded, Scopus)

120. Chemotherapy in advanced breast carcinoma: Efficacy of primary and secondary or tertiary docetaxel use.

AYDINER A., Topuz E., Argon A., SAİP P. M., TAŞ F., ERALP Y., et al.

ANNALS OF ONCOLOGY , cilt.11, ss.37, 2000 (SCI-Expanded, Scopus)

121. Neurologic late toxicity in testicular cancer patients treated with bleomycin, etoposide and cisplatin (bep) combination chemotherapy.

Bavbek S., BAŞARAN M., Saip S., ERALP Y., Sakar B., Onat H.

ANNALS OF ONCOLOGY , cilt.11, ss.78, 2000 (SCI-Expanded, Scopus)

122. Correlations of serum CA125 level and computerized tomography (CT) imaging with laparotomic findings following intraperitoneal chemotherapy in patients with ovarian cancer

Topuz E., Aydiner A., SAİP P. M., ERALP Y., TAŞ F., Salihoglu Y., et al.

EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY , cilt.21, sa.6, ss.599-602, 2000 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

123. Rectal cancer in young patients: Characteristics and outcome.

Alici S., Kaytan E., Sakar B., Bulutlar L., ERALP Y., Argon A., et al.

ANNALS OF ONCOLOGY , cilt.11, ss.56, 2000 (SCI-Expanded, Scopus)

124. Survival and prognostic factors in patients with Hodgkin's disease

ERALP Y., Bavbek S., Basaran M., Uygun K., Kaytan E., Çamlica H., et al.

EUROPEAN JOURNAL OF CANCER , cilt.35, 1999 (SCI-Expanded, Scopus)

125. Efficacy of combination therapy with omeprazole, amoxicillin and clarithromycin for treatment of patients with Helicobacter pylori associated gastritis and duodenal ulcer disease

Eralp Y., Davutoglu C., Uzunismail H., Oktay E.

Turkish Journal of Gastroenterology , cilt.10, sa.1, ss.27-31, 1999 (Scopus, TRDizin)

126. Factors influencing the distribution of metastases and survival in extensive disease small cell lung cancer

TAŞ F., AYDINER A., Topuz E., Camlica H., SAİP P. M., ERALP Y.

ACTA ONCOLOGICA , cilt.38, sa.8, ss.1011-1015, 1999 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

127. Evaluation of chronic gastritis in patients with Helicobacter pylori associated gastritis, gastroduodenitis and duodenal ulcer disease

Bagatur N., Eralp Y., ÇELİK A. F., DOBRUCALI A. M., Bal K., TUNCER M., et al.

Turkish Journal of Gastroenterology , cilt.10, sa.1, ss.32-35, 1999 (Scopus, TRDizin)

128. [Meta-analysis of determining the pathogen eradicating efficacy of various therapeutic regimens in Helicobacter pylori infection].

Dobrucali A., Canbakan B., Canbakan M., Bagatur N., Uzunismail H., Eralp Y., et al.

Wiener medizinische Wochenschrift (1946) , cilt.148, sa.20, ss.464-8, 1998 (Scopus)

129. One-day high-dose combined therapy of Helicobacter pylori infection

DOBRUCALI A. M., Tuncer M., ERALP Y., Goksel S., Altin M., Dinc I.

DIGESTIVE DISEASES AND SCIENCES , cilt.42, sa.10, ss.2169-2170, 1997 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 37

1. Daha önce Tedavi Edilmemiş PD-L1- pozitif ilerlemiş üçlü negatif meme kanserinde (TNBC) sacituzumab govitecan (SG)+ pembrolizumab (pembro)ile kemoterapi + pembro karşılaştırılması: randomize faz 3 ASCENT-04/ KEYNOTE -D19çalışmasının birincil sonuçları

Eralp Y., Tolaney S., Azambuja E. D., Kalinsky K.

9. Ulusal Immunoterapi ve Onkoloji Kongresi, İskele, Kıbrıs (Kktc), 29 Ekim - 02 Kasım 2025, ss.95-96, (Özet Bildiri)

2. clinical characteristics and prognosis in interval detected breast cancer patients: a single institution cohort analysis

Eralp Y., Bayrakçeken S., Türker Karayazı K., Içten S. G., Tokat F., Bese F. N., et al.

san antanio breast cancer symposium, Texas, Amerika Birleşik Devletleri, 9 - 12 Aralık 2025, ss.1-3, (Özet Bildiri)

3. Artificial intelligence algorithms for recurrence risk score prediction in early-stage breast cancer: A multicenter study of 437 cases

Bayram E., Basaran G., Gokmen E., Mandel N. M., Oyan B., Uskent N., et al.

Special Clinical Science Symposia, ELECTR NETWORK, 29 Mayıs 2024, (Özet Bildiri)

4. First-line (1L) ribociclib (RIB) plus endocrine therapy (ET) vs combination chemotherapy (combo CT) in HR+/HER2L advanced breast cancer (ABC): A post hoc analysis of Asian and non-Asian patients (pts) from the phase II RIGHT choice trial

Yap Y., Im S., Lu Y., Azim H. A., ERALP Y., Kanakasetty G. B., et al.

Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Singapur, 1 - 03 Aralık 2023, cilt.34, (Özet Bildiri) Sürdürülebilir Kalkınma

5. Quality of life (QOL) analysis from the phase II RIGHT choice study of first-line ribociclib (RIB) plus endocrine therapy (ET) vs combination chemotherapy (combo CT) in aggressive HR+/HER2-advanced breast cancer (ABC)

ERALP Y., Abdel-Razeq H., Im S., Rihani J., Lu Y., Yap Y. S., et al.

Congress of the European-Society-for-Medical-Oncology (ESMO), Madrid, İspanya, 20 - 24 Ekim 2023, cilt.34, (Özet Bildiri)

6. First-line ribociclib (RIB) plus endocrine therapy (ET) vs combination chemotherapy (combo CT) in aggressive HR+/HER2-advanced breast cancer (ABC): A subgroup analysis of patients (pts) with or without visceral crisis from the phase II RIGHT choice study

Azim H. A., El Saghir N. S., Yap Y. S., ERALP Y., Im S., Sandhu M. S., et al.

Congress of the European-Society-for-Medical-Oncology (ESMO), Madrid, İspanya, 20 - 24 Ekim 2023, cilt.34, (Özet Bildiri) Sürdürülebilir Kalkınma

7. Outcomes with first-line (1L) ribociclib (RIB) plus endocrine therapy (ET) vs physician's choice combination chemotherapy (combo CT) by age in pre/perimenopausal patients (pts) with aggressive HR+/HER22-advanced breast cancer (ABC): A subgroup analysis of the RIGHT Choice trial.

El Saghir N. S., Yap Y. S., ERALP Y., Im S., Azim H. A., Rihani J., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 2 - 06 Haziran 2023, cilt.41, (Özet Bildiri) Sürdürülebilir Kalkınma

8. Primary results from the randomized Phase II RIGHT Choice trial of premenopausal patients with aggressive HR+/HER2-advanced breast cancer treated with ribociclib plus endocrine therapy vs physician's choice combination chemotherapy

Lu Y., Mahidin E. I. B. M., Azim H., ERALP Y., Yap Y., Im S., et al.

San Antonio Breast Cancer Symposium, San-Antonio, Kuzey Mariana Adaları, 6 - 10 Aralık 2022, cilt.83, (Özet Bildiri) Sürdürülebilir Kalkınma

9. Demographic and clinical features of patients with metastatic HER2 positive breast cancer: a retrospective multicenter registry study of the Turkish Oncology Group

Eralp Y., Dogan I., AKSOY S., Cakar B., Basaran G., Ercelep O., et al.

San Antonio Breast Cancer Symposium, San-Antonio, Kuzey Mariana Adaları, 6 - 10 Aralık 2022, (Özet Bildiri)

10. Phase Ia/Ib study of RS-0139, a novel tumor-targeted delivery of docetaxel, in patients with recurrent, locally advanced, or metastatic non-small cell lung cancer (NSCLC)

Orer H. S., Nomak G., Oksuzoglu B., Senturk R., ERALP Y., Yumuk F., et al.

Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 9 - 13 Eylül 2022, (Özet Bildiri)

11. Retrospective analysis of ribociclib and letrozole as first-line therapy in patients with hormone receptor (HR) positive metastatic breast cancer (MBC) within a managed access program (MAP) in Turkey.

Basaran G., Demirci U., Yildiz F., Cicin I., Aktas B. Y., Ozturk B., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 - 31 Mayıs 2020, cilt.38, (Özet Bildiri)

12. Determine the impact of hybrid capture-based comprehensive genomic profiling (CGP) on the treatment strategies in patients with solid tumors: A national, multicenter, retrospective study.

Disel U., Kose F., Bilici A., ÖZGÜROĞLU M., Saglam S., Seker M., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 - 31 Mayıs 2020, (Özet Bildiri)

13. Ribociclib for the treatment of hormone receptor-positive refractory advanced breast cancer: Managed access programme in Turkey

Demirci U., GÖKMEN E., Eralp Y., Gunduz S., SEZGİN GÖKSU S., KORKMAZ T., et al.

42nd Annual San Antonio Breast Cancer Symposium, San-Antonio, Kuzey Mariana Adaları, 9 - 14 Aralık 2019, cilt.80, (Özet Bildiri) Sürdürülebilir Kalkınma

14. Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in pre-/perimenopausal patients with HR+, HER2-inoperable locally advanced breast cancer (ABC): RIGHT choice study

Lu Y., Malwinder S. S., Azim H., Eralp Y., Im S., Yap Y. S., et al.

European-Society-for-Medical-Oncology (ESMO) Asia Congress, Singapore, Singapur, 22 - 24 Kasım 2019, (Özet Bildiri)

15. Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with HR+, HER2-inoperable locally advanced or metastatic breast cancer: RIGHT choice study

El Saghir N., Malwinder S., Azim H., Eralp Y., Im S., Yap Y. S., et al.

44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, İspanya, 27 Eylül - 01 Ekim 2019, ss.140-141, (Özet Bildiri)

16. Is there any prognostic significance in pleural involvement and/or effusion (Ple-I/E) in patients with ALK-positive NSCLC?

Kilickap S., Basal F. B., DEMİRKAZIK A., Gursoy P., Demirci U., ERMAN M., et al.

44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, İspanya, 27 Eylül - 01 Ekim 2019, ss.637, (Özet Bildiri)

17. The efficacy and safety of crizotinib in patients with ROS1 positive advanced stage NSCLC: The real-world experience from Turkey

Kilickap S., Olmez O. F., Cicin I., Demirci U., ALAN Ö., ÇABUK D., et al.

43rd ESMO Congress (ESMO), Munich, Almanya, 19 - 23 Ekim 2018, cilt.29, ss.505, (Özet Bildiri)

18. Long-term effective local control in patients presenting with T4 disease and treated with breast-conserving therapy after neoadjuvant chemotherapy

TÜKENMEZ M., Trablus D. C., Ozkurt E., CABIOĞLU N., Dogan S., EMİROĞLU S., et al.

19th Annual Meeting of the American-Society-of-Breast-Surgeons, Florida, Amerika Birleşik Devletleri, 2 - 06 Mayıs 2018, cilt.25, ss.530-531, (Özet Bildiri)

19. The prognostic impact of chemotherapy induced amenorrhea in women treated with early stage breast cancer

Ordu C., Pilanci K. N., Elbuken F., Alco G., Koksal U. I., Ilgun S., et al.

42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid, İspanya, 8 - 12 Eylül 2017, (Özet Bildiri)

20. Follow-up of chemotherapy induced changes in anti-Mullerian hormone, antral follicle number and ovary volume in premenopausal breast cancer patients

Elbuken F., Ordu C., Sarsenov D., Ilgun S., Pilanci K., Erdogan Z., et al.

41st Annual Congress of the European-Society-for-Medical-Oncology (ESMO), Copenhagen, Danimarka, 7 - 11 Ekim 2016, cilt.27, (Özet Bildiri) Sürdürülebilir Kalkınma

21. Neoadjuvam kemoterapi öncesi biyopsi ile doğrulanmış aksiller metastazı olan hangi hasta grubunda tedavi sonrası aksiller diseksiyon göz ardı edilebilir?

Karanlık H., Özgür İ., Bademler S., Şen F., Eralp Y., Fayda M., et al.

20. Ulusal Cerrahi Kongresi, 2016, Antalya, Türkiye, 13 - 17 Nisan 2016, ss.1, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

22. Metaplastic breast carcinoma versus triple nehative breast cancer survival and response to treatment

AYDINER A., ŞEN F., ÇİFTÇİ R., RÜMEYSA Ç., ERALP Y., SAİP P. M., et al.

MEDİCİNE, 01 Aralık 2015, (Özet Bildiri) Sürdürülebilir Kalkınma

23. Concominant Chemoradiotherapy with Etoposide Cisplatin versus Docetaxel Cisplatin in Locally Advanced Non Small Cell Lung Cancer

ERALP Y., ŞEN F., MAKBULE T., ÖZKAYA K., BERKER Ö., ORAL E. N., et al.

NSCLC, 09 Eylül 2015 Sürdürülebilir Kalkınma

24. Does adjuvant chemotherapy induced amenorrhea effect survival in operated premenopausal breast cancer patients

ORDU Ç., ALÇO G., KN P., S, İ., D, S., F, Ç., et al.

European Cancer Congress, 01 Eylül 2015, cilt.322, (Özet Bildiri) Sürdürülebilir Kalkınma

25. Is administration of trastuzumab an independent risk factor for developing osteonecrosis of the jaw among metastatic breast cancer patients under zoledronic acid treatment

G, A., ORDU Ç., D, S., F, Ç., ERDOĞAN Z., AĞACAYAK F., et al.

EUR J SUR ONCOL, 01 Mayıs 2015, cilt.94, (Özet Bildiri) Sürdürülebilir Kalkınma

26. Aksiller metastazı bulunan hangi hastalarda neoadjuvan kemoterapi sonrasında aksiller diseksiyon yapılmayabilinir?

Karanlık H., Özgür İ., Fayda M., Yavuz E., Mudun A., Saip P. M., et al.

19. Ulusal Cerrahi Kongresi, Antalya, Türkiye, 16 - 20 Nisan 2014, ss.1-1751, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

27. Magnetic resonance imaging as a predictor of pathologic response rates in patients treated with neoadjuvant chemotherapy

KARANLIK H., SAİP P. M., Fayda M., YAVUZ E., ERALP Y., Kucucuk S., et al.

9th European Breast Cancer Conference (EBCC), Glasgow, İngiltere, 19 - 21 Mart 2014, cilt.50, (Özet Bildiri)

28. Immunohistochemically Defined T1N0 Breast Cancer Subgroups Have Different Clinical Outcomes. A Retrospective Turkish Oncology Group Study

BAŞARAN G., Okkan S., Caglar H., Benekli M., Gumus M., Haydaroglu A., et al.

32nd Annual San Antonio Breast Cancer Symposium, San-Antonio, Kuzey Mariana Adaları, 9 - 13 Aralık 2009, cilt.69, (Özet Bildiri)

29. Is the sentinel lymph node biopsy accurate for patients with initially clinically axilla-positive locally advanced breast cancer after neoadjuvant chemotherapy?

Ozmen V., Muslumanoglu M. E., Igci A., Canbay E., ÖZÇINAR B., Mudun A., et al.

31st Annual San Antonio Breast Cancer Symposium, San-Antonio, Kuzey Mariana Adaları, 10 - 14 Aralık 2008, cilt.69, (Özet Bildiri)

30. MAPK expression is associated with poor outcome in patients with hormone receptor negative breast cancer

ERALP Y., Derin D., ÖZLÜK M. Y., Yavuz E., Gulley N., SAİP P. M., et al.

30th Annual San Antonio Breast Cancer Symposium, San-Antonio, Kuzey Mariana Adaları, 13 - 16 Aralık 2007, cilt.106, (Özet Bildiri)

31. Factors related with recurrence after complete pathologic response to post- operative chemotherapy in patients with epithelial ovarian cancer

Karagol H., SAİP P. M., Uygun K., ERALP Y., TOPUZ S., Berkman S., et al.

31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Türkiye, 29 Eylül - 03 Ekim 2006, cilt.17, ss.174, (Özet Bildiri)

32. Induction chemotherapy followed by chemoradiotherapy in patients with stage IIIA-B non-small cell lung cancer (NSCLC)

Saglam E. K., AYDINER A., Sakallioglu B., Ozturk B., ERALP Y., SAİP P. M., et al.

31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Türkiye, 29 Eylül - 03 Ekim 2006, cilt.17, ss.229, (Özet Bildiri)

33. The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer

Karagol H., Saip P., Uygun K., Caloglu M., Eralp Y., TAŞ F., et al.

31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Türkiye, 29 Eylül - 03 Ekim 2006, cilt.17, ss.174, (Özet Bildiri) Sürdürülebilir Kalkınma

34. Serum levels of leptin and proinflammatory cytokinesin advanced stage non-small cell lung cancer.

Topuz E., TAŞ F., Argon A., Yildiz D., OĞUZ SOYDİNÇ H., Yasasever V., et al.

41st Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, Amerika Birleşik Devletleri, 13 - 17 Mayıs 2005, cilt.23, (Özet Bildiri)

35. Body mass index (BMI) is a predictor for response to neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger.

ERALP Y., Smith T., Kau S., Valero V., Buzdar A., Hortobagyi G., et al.

40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, Amerika Birleşik Devletleri, 5 - 08 Haziran 2004, cilt.22, (Özet Bildiri)

36. Induction chemotherapy with carboplatin and weekly paclitaxel followed by concomitant chemoradiation in locally advanced non-small cell lung cancer.

AYDINER A., Topuz E., ERALP Y., Kaytan E., ORAL E. N., Kizir A.

40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, Amerika Birleşik Devletleri, 5 - 08 Haziran 2004, cilt.22, (Özet Bildiri)

37. Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER-2/neu in a murine mammary carcinoma model

Eralp Y., Wang X., Wang J., Maughan M., Polo J., Lachman L.

27th Annual Charles A Colman San Antonio Breast Cancer Symposium, San-Antonio, Kuzey Mariana Adaları, 8 - 11 Aralık 2004, cilt.88, (Özet Bildiri) Sürdürülebilir Kalkınma

Metrikler

Yayın

168

Yayın (WoS)

150

Yayın (Scopus)

122

Atıf (WoS)

1113

H-İndeks (WoS)

Atıf (Scopus)

1575

H-İndeks (Scopus)

Toplam Atıf Sayısı

1575

Açık Erişim

BM Sürdürülebilir Kalkınma Amaçları

Yayınlar & Eserler